Alzheimer disease and cognitive impairment associated with diabetes mellitus type 2: Associations and a hypothesis;Enfermedad de Alzheimer y deterioro cognitivo asociado a la diabetes mellitus de tipo 2: Relaciones e hipótesis

Neurologia

Volumn 29, Issue 9, 2014, Pages 567-572

  Dominguez R O ^a   Pagano, M A ^a   Marschoff, E R ^a   Gonzalez S E ^a   Repetto, M G ^a   Serra, J A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Alzheimer's disease; Cerebral glucose metabolism; Diabetes mellitus type 2; Hypoglycaemic drugs; Insulin resistance; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; INSULIN RECEPTOR;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DIABETIC NEUROPATHY; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEIN DEFECT; SHORT SURVEY; COGNITION DISORDERS; COMPLICATION; DEMENTIA; DISEASE COURSE; METABOLISM;

ALZHEIMER DISEASE; COGNITION DISORDERS; DEMENTIA; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; OXIDATIVE STRESS;

EID: 84922514950     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2013.05.006     Document Type: Short Survey

References (51)

1. Bell D.S. Stroke in the diabetic patient. Diabetes Care 1994, 17:213-219.
2. Knopman D., Boland L.L., Mosley T., Howard G., Liao D., Szklo M., et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001, 56:42-44.
3. Peila R., Rodríguez B.L., Launer L.J. Type 2 diabetes. APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002, 51:1256-1262.
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
5. Alexander C.M., Landsman P.B., Teutsch S.M., Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210-1214.
6. Miyakawa T. Vascular pathology in Alzheimer's disease. Psychogeriatrics 2010, 10:39-44.
7. Tuppo E.E., Arias H.R. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005, 37:289-305.
8. Luchsinger J.A. Diabetes, related conditions, and dementia. J Neurol Sci 2010, 299:35-38.
9. Kapogiannis D., Mattson M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol 2011, 10:187-198.
10. Fernández-Gamba A., Leal M.C., Morelli L., Castaño E.M. Insulin-degrading enzyme: Structure-function relationship and its possible roles in health and disease. Curr Pharm Des 2009, 15:3644-3655.
11. Honig L.S., Tang M.X., Albert S., Costa R., Luchsinger J., Manly J., et al. Stroke and the risk of Alzheimer disease. Arch Neurol 2003, 60:1707-1712.
12. Hachinski V.C., Potter P., Merskey H. Leuko-araiosis. Arch Neurol 1987, 44:21-23.
13. Domínguez R.O., Famulari A.L., Gallo A., García G., Bartolomé E., D'Abbraccio G., et al. Early onset of leuko-araiosis in hypertensive patients. Arch Neurol 1993, 50:13-14.
14. Reijmer Y.D., van den Berg E., Ruis C., Jaap Kappelle L., Biessels G.J. Cognitive dysfunction in patients with type 2 diabetes. Diabetes Metab Res Rev 2010, 27:195-202.
15. Verdelho A., Madureira S., Moleiro C., Ferro J.M., Santos C.O., Erkinjuntti T., et al. White matter changes and diabetes predict cognitive decline in the elderly: The LADIS study. Neurology 2010, 75:160-167.
16. Brands A.M., Biessels G.J., Kappelle L.J., de Haan E.H., de Valk H.W., Algra A., et al. Cognitive functioning and brain MRI in patients with type 1 and type 2 diabetes mellitus: A comparative study. Dement Geriatr Cogn Disord 2007, 23:343-350.
17. Tiehuis A.M., Vincken K.L., van den Berg E., Hendrikse J., Manschot S.M., Mali W.P., et al. Cerebral perfusion in relation to cognitive function and type 2 diabetes. Diabetologia 2008, 51:1321-1326.
18. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 2004, 490:115-125.
19. Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. J Alzheimers Dis 2005, 8:247-268.
20. Janson J., Laedtke T., Parisi J.E., O'Brien P., Petersen R.C., Butler P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481.
21. Kubota T., Kubota N., Moroi M., Terauchi Y., Kobayashi T., Kamata K., et al. Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation 2003, 107:3073-3080.
22. Dick P.J., Karnes J.L., O'Brien P., Okazaki H., Lais A., Engelstad J. The spatial distribution of fiber loss in diabetic polineuropathy suggests ischemia. Ann Neurol 1986, 19:440-449.
23. Brownlee M., Cerami A., Vlassara H. Advanced glycosilation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-1321.
24. Low P.A., Nickander K.K. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 1991, 40:873-877.
25. Pagano M.A., Basile R.M., Krinsky F., Dacordi H., Yorio A., Sánchez G.G. Compromiso del tronco cerebral en la Diabetes Mellitus. Rev Soc Arg Diabetes 1988, 22:53.
26. Asvold B.O., Sand T., Hestad K., Bjorgaas M.R. Cognitive function in type 1 diabetic adults with early exposure to severe hypoglycemia: A 16-year follow-up study. Diabetes Care 2010, 33:1945-1947.
27. Lovestone S., Reynolds C.H. The phosphorylation of tau (τ): A critical stage in neurodevelopmental and neurodegenerative processes. Neuroscience 1997, 78:309-324.
28. Sonnen J.A., Larson E.B., Brickell K., Crane P.K., Woltjer R., Craft S. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 2009, 66:315-322.
29. Ba-Tin L., Strike P., Tabet N. Diabetic peripheral microvascular complications: Relationship to cognitive function. Cardiovasc Psychiatry Neurol 2011, 723434.
30. Serra J.A., Marschoff E.R., Domínguez R.O., Guareschi E.M., Famulari A.L., Pagano M.A., et al. Oxidative stress in Alzheimer's and vascular dementias: Masking of the antioxidant profiles by a concomitant type ii diabetes mellitus condition. J Neurol Sci 2004, 218:17-24.
31. Domínguez R.O., Marschoff E.R., Guareschi E.M., Famulari A.L., Pagano M.A., Serra J.A. Homocysteine, vitamin B12 and folate in Alzheimer's and vascular dementias: The paradoxical effect of the superimposed type ii diabetes mellitus condition. Clin Chim Acta 2005, 359:163-170.
32. Cankurtaran M., Yesil Y., Kuyumcu M.E., Oztürk Z.A., Yavuz B.B., Halil M., et al. Altered levels of homocysteine and serum natural antioxidants links oxidative damage to Alzheimer's disease. J Alzheimers Dis 2013, 33:1051-1058.
33. Domínguez R.O., Marschoff E.R., Guareschi E.M., Repetto M.G., Famulari A.L., Pagano M.A., Serra J.A. Insulin, glucose and glycated hemoglobin in Alzheimer's and vascular dementia with and without superimposed Type II diabetes mellitus condition. J Neural Transm. 2008, 115:77-84.
34. De Felice F.G., Vieira M.N.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of A-β oligomers. Proc Natl Acad Sci USA. 2009, 106:1971-1976.
35. Serra J.A., Domínguez R.O., Marschoff E.R., Guareschi E.M., Famulari A.L., Boveris A. Systemic oxidative stress associated with the neurological diseases of aging. Neurochem Res. 2009, 34:2122-2132.
36. Kickstein E., Krauss S., Thornhill P., Rutschow D., Zeller R., Sharkey J., et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA. 2010, 107:21830-21835.
37. Gupta A., Bisht B., Dey C.S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011, 60:910-920.
38. Li J., Deng J., Sheng W., Zuo Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav. 2012, 10:564-574.
39. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012, 69:29-38.
40. Ramasamy R., Vannucci S.J., Yan S.S., Herold K., Yan S.F., Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15:16R-28R.
41. Yan S., Chen X., Schmidt A., Brett J., Godman G., Scott C., et al. Glycated tau in Alzheimer's disease: A mechanism for induction of oxidative stress. Proc Natl Acad Sci USA. 1994, 91:7787-7791.
42. Munch G., Schinzel R., Loske C., Wong A., Duray N., Riederer P., et al. Alzheimer's disease synergistics effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm. 1998, 105:439-461.
43. Rolo A., Palmeira C. Diabetes and mitocondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol. 2006, 212:167-178.
44. de Lustig E.S., Serra J.A., Kohan S., Canziani G., Famulari A.L., Domínguez R.O. Copper-zinc superoxide dismutase activity in red blood cells and serum in demented patients and in aging. J Neurol Sci. 1993, 115:18-25.
45. Serra J.A., Domínguez R.O., de Lustig E.S., Guareschi E.M., Famulari A.L., Bartolomé E.L., et al. Parkinson's disease is associated with oxidative stress: Comparison of peripheral antioxidant profiles in living Parkinson's. Alzheimer's and vascular dementia patients. J Neural Transm. 2001, 108:1135-1148.
46. Sies H. Oxidative stress: from basic research to clinical application. Am J Med. 1991, 91:31-38S.
47. Hanbali A., Al-Khasawneh K., Cole-Johnson C., Divine G., Ali H. Protective effect of diabetes against metastasis in patients with non-small cell lung cancer. Arch Intern Med 2007, 167:513.
48. Waters K.M., Henderson B.E., Stram D.O., Wan P., Kolonel L.N., Haiman C.A. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009, 169:937-945.
49. Sanz C., Andrieu S., Sinclair A., Hanaire H., Vellas B. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 2009, 73:1359-1366. Real fr Study Group.
50. Baraka A., ElGhotny S. Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats. Eur J Pharmacol 2010, 64:123-127.
51. Domínguez R.O., Marschoff E.R., González S.E., Repetto M.G., Serra J.A. Type 2 Diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients. Diabetes Res Clin Pract. 2012, 98:68-74.